A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- Breast Neoplasms
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a study which consists of phase ?study?dose escalation stage) and phase 2a study (expansion stage)? Phase 1 study will adopt the classical 3+3 dose escalation design, exploring the safety and tolerance of 5 dose cohorts (25mg, 75mg, 150mg, 250mg and 400mg) in subjects with advanced solid tum...
This is a study which consists of phase ?study?dose escalation stage) and phase 2a study (expansion stage)? Phase 1 study will adopt the classical 3+3 dose escalation design, exploring the safety and tolerance of 5 dose cohorts (25mg, 75mg, 150mg, 250mg and 400mg) in subjects with advanced solid tumor and determining the maximum tolerated dose of BPI-1178 for phase 2a study. Phase 2a is an expansion study in subjects of HR+/HER2- breast cancer using 3+3 design, to evaluate the efficacy and safety of BPI-1178 in combination with endocrine therapy. Cohort A is BPI-1178 in combination with fulvestrant for advanced or recurrent HR+/HER2- breast cancer after failure or intolerance of first-line standard therapy. Cohort B is BPI-1178 in combination with letrozole for advanced or recurrent HR+/HER2- breast cancer as first-line treatment. Phase 1 and 2a consist of screening period (28 days before enrollment), treatment period and follow up period (every 3 months until death or the end of study). Subjects will receive BPI-1178 daily for 3 weeks, followed by 1 week-off treatment. Once the maximum tolerated dose (MTD) is reached in phase 1, phase 2a study will explore the dose of BPI-1178 from MTD to MTD-1 and MTD-2 level in combination with fulvestrant or letrozole. Dose limiting toxicity (DLT) will be recorded for the single dose period of 7 days and the multiple dose period up to 28 days in phase 1 study, as well as 28 days after the first dose of BPI-1178 in phase 2a. Efficacy will be evaluated by RECIST v1.1 and the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) every 2 months. Adverse events will be monitored throughout the trial. Other exploration of pharmacokinetic information will be assessed throughout the trial.
Tracking Information
- NCT #
- NCT04282031
- Collaborators
- Not Provided
- Investigators
- Not Provided